the therapeutic revolution in management of higher risk mds: a focus on immunotherapy
Published 3 years ago • 509 plays • Length 1:00:07Download video MP4
Download video MP3
Similar videos
-
3:08
the treatment protocol for higher risk mds
-
43:11
post #ash21 by the iach: a focus on mds
-
6:05
the immune system's role in higher-risk mds
-
40:20
high-risk mds follonig car t cells in patients with rr dlbcl
-
4:44
immunotherapy in mds
-
22:08
a unified approach to higher risk mds: standard and emerging therapies
-
24:04
my approach to mds management
-
3:31
promising treatment options emerging for higher-risk mds & the value of clinical trials
-
11:02
how to obtain viable cardiomyocytes from resected mouse hearts
-
6:45
mds survivor: cindy sargeant
-
3:54
life with mds: jill shares how her family helped her overcome an mds diagnosis
-
1:41
novel therapies for high-risk mds
-
2:37
esas for the management of lower-risk mds
-
2:04
state-of-the-art treatment for hr-mds
-
3:38
a new set of treatment options for low-risk mds
-
55:53
diagnosis and management of systemic mastocytosis: what's new in 2024?
-
1:02
update on treatments for high- and low-risk mds
-
43:12
latest therapeutic advances in myeloma
-
2:11
new therapeutic options for low-risk mds
-
2:02
unmet needs in high-risk mds and future therapeutic strategies
-
5:05
higher-risk mds in 2021: pevonedistat, sabatolimab & apr-246